[1]刘春秋 熊双 刘剑刚 董国菊.射血分数保留性心力衰竭的诊断的研究进展[J].心血管病学进展,2021,(9):784-787.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
　LIU Chunqiu,XIONG Shuang,LIU Jiangang,et al.Diagnosis of Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2021,(9):784-787.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
点击复制

射血分数保留性心力衰竭的诊断的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年9期
页码:
784-787
栏目:
综述
出版日期:
2021-09-25

文章信息/Info

Title:
Diagnosis of Heart Failure with Preserved Ejection Fraction
文章编号:
202101010
作者:
刘春秋1; 2 熊双1; 2 刘剑刚1 董国菊1
(1.中国中医科学院西苑医院 国家中医临床心血管病医学研究中心,北京 100091;2.中国中医科学院研究生院,北京 100700)
Author(s):
LIU Chunqiu1; 2;  XIONG Shuang1; 2; LIU Jiangang1; DONG Guoju1
(1.Xiyuan Hospital,China Academy of Chinese Medical Sciences,National Center for Clinical Cardiovascular Disease of Traditional Chinese Medicine,Beijing 100091 ,China; 2.Graduate School of China Academy of Chinese Medical Sciences,Beijing 100700,China)
关键词:
射血分数保留性心力衰竭; 射血分数; 诊断
Keywords:
Heart failure with preserved ejection fraction; Ejection fraction; Diagnosis
DOI:
10.16806/j.cnki.issn.1004-3934.2021.09.000
摘要:
射血分数保留性心力衰竭（HFpEF）是一种机制复杂和临床表现多样的心力衰竭，目前，其患者人数约占全部心力衰竭的一半，是常见的心力衰竭类型之一。由于HFpEF患者临床表现具有高度异质性，以及常被用来诊断心力衰竭的指标和检查（如脑钠肽和超声心动图）被发现并不具备诊断HFpEF的特异性，这使得很多HFpEF患者漏诊和误诊,从而延误了HFpEF患者的及时治疗。为了能明确HFpEF的诊断，近些年出现了HFA-PEFF和H2FPEF两种诊断评分系统。但由于对HFpEF机制认识的不足，缺乏特异性指标以及相关检查技术要求较高等原因导致HFpEF的诊断标准尚未统一。现从HFpEF的诊断要点、相关的评分系统以及研究进展等方面对HFpEF的研究进行综述。
Abstract:
Heart failure with preserved ejection fraction(HFpEF) is a kind of heart failure with complex mechanism and various clinical phenotypes. At present,the number of patients accounts for about half of all heart failure,which is one of the common types of heart failure. Because the clinical manifestations of HFpEF patients are highly heterogeneous,and the indexes and examinations(such as brain natriuretic peptide and echocardiography) often used to diagnose heart failure are found to be not specific for diagnosing HFpEF,many HFpEF patients are missed and misdiagnosed,thus delaying the treatment of HFpEF patients. In recent years,two diagnostic scoring systems,HFA-PEFF and H 2FPEF,have appeared in order to clarify the diagnosis of HFpEF. However,due to the lack of understanding of the mechanism of HFpEF,the lack of specific indicators and the high requirements of related examination techniques,the diagnostic criteria of HFpEF have not been unified. This paper reviews the diagnostic points,related scoring systems and research progress of HFpEF.

参考文献/References:

[1]Ponikowski P,Voors AA,Anker SD,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure :the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). Developed with the special contribution of the Heart Failure Association(HFA) of the ESC[J]. Eur J Heart Fail,2016,18(8):891-975.

[2]Heidenreich PA,Albert NM,Allen LA,et al. Forecasting the impact of heart failure in the United States:a policy statement from the American Heart Association[J]. Circ Heart Fail,2013,6(3):606-619.

[3]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会,等. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志,2018,46(10):10760-10789.

[4]陈浩然,麦妙美,李格丽,等. 射血分数保留的心力衰竭患者肺功能异常特征研究[J]. 中国全科医学,2020,4:447-452.

[5]Salah K,Stienen S,Pinto YM,et al. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction[J]. Heart,2019,105(15):1182-1189.

[6]范春炜,陈璟,车春香,等. BNP/NT-proBNP在老年心力衰竭患者心功能评估中的应用价值[J]. 中华临床医师杂志(电子版),2020,14(6):439-443.

[7]Pieske B,Tsch?pe C,de Boer RA,et al. How to diagnose heart failure with preserved ejection fraction:the HFA-PEFF diagnostic algorithm:a consensus recommendation from

the Heart Failure Association(HFA) of the European Society of Cardiology(ESC)[J].

Eur J Heart Fail,2020,22(3):391-412.

[8]Vaishnav J,Chasler JE,Lee YJ,et al. Highest obesity category associated with largest decrease in N-terminal pro-B-type natriuretic peptide in patients hospitalized with heart failure with preserved ejection fraction[J]. J Am Heart Assoc,2020,9(15):e015738.

[9]Lala RI,Lungeanu D,Darabantiu D,et al. Galectin-3 as a marker for clinical prognosis

and cardiac remodeling in acute heart failure[J]. Herz, 2018,43(2):146-155.

[10]Kanukurti J,Mohammed N,Sreedevi NN,et al. Evaluation of galectin-3 as a novel diagnostic biomarker in patients with heart failure with preserved ejection fraction[J]. J Lab Physicians,2020,12(2):126-132.

[11]Zhao YN,Li H,Zhao C,et al. ST2 silencing aggravates ventricular remodeling and

chronic heart failure in rats by mediating the IL-33/ST2 axis[J]. J Tissue Eng Regen Med,2020,14(9):1201-1212.

[12]Najjar E,Faxén UL,Hage C,et al. ST2 in heart failure with preserved and reduced

ejection fraction[J]. Scand Cardiovasc J,2019,53(1):21-27.

[13]Kop’eva KV,Teplyakov AT,Grakova EV,et al. Role of ST2 biomarker for the evaluation of myocardial remodeling in patients with ischemic heart failure with preserved ejection fraction[J]. Kardiologiia,2018,S10:33-43.

[14]Ristagno G,Fumagalli F,Bottazzi B,et al. Pentraxin 3 in cardiovascular disease[J]. Front Immunol, 2019,10:823.

[15]Louren?o P,Pereira J,Ribeiro A,et al. C-reactive protein decrease associates with

mortality reduction only in heart failure with preserved ejection fraction[J]. J Cardiovasc

Med(Hagerstown),2019,20(1):23-29.

[16]Garlanda C,Bottazzi B,Magrini E,et al. PTX3,a humoral pattern recognition molecule,in innate immunity,tissue repair,and cancer[J]. Physiol Rev,2018,98(2):623-639.

[17]Matsubara J,Sugiyama S,Nozaki T,et al. Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular

ejection fraction[J]. J Am Heart Assoc,2014,3(4):e000928.

[18]Eddy AC,Trask AJ. Growth differentiation factor-15 and its role in diabetes and

cardiovascular disease[J]. Cytokine Growth Factor Rev,2021,57:11-18.

[19]Rabkin SW,Tang JKK. The utility of growth differentiation factor-15,galectin-3,and

sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction :a systematic review[J]. Heart Fail Rev, 2021,26(4):799-812.

[20]Chan MM,Santhanakrishnan R,Chong JP,et al. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction[J]. Eur J Heart Fail,2016,18(1):81-88.

相似文献/References:

[1]孙慧雪 郑美芳 李海 孙磊 顾翔.远程医疗应用于射血分数保留性心力衰竭的现状及进展[J].心血管病学进展,2020,(3):251.[doi:10.16806/j.cnki.issn.1004-3934.20.03.009]
　SUN Huixue,ZHENG Meifang,LI Hai,et al.Status Progress of Telemedicine in Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2020,(9):251.[doi:10.16806/j.cnki.issn.1004-3934.20.03.009]
[2]菲尔凯提·玉山江李昊穆叶赛·尼加提.射血分数保留性心力衰竭合并糖尿病的研究进展[J].心血管病学进展,2020,(4):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
　FEIERKAITI·Yushanjiang,LIHao,MUYESAI.Nijiati.Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(9):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
[3]高可 杨蕾 姚新叶 郑小璞.射血分数保留性心力衰竭动物模型的研究进展[J].心血管病学进展,2020,(8):834.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.013]
　GAO Ke,YANG Lei,YAO Xinye,et al.Advances in Animal Models ofHeart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2020,(9):834.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.013]
[4]宋雨 李耘 马丽娜.老年人衰弱和射血分数保留性心力衰竭病理生理学机制的研究进展[J].心血管病学进展,2022,(1):38.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.010]
　SONG Yu,LI Yun,MA Lina.Pathophysiological Mechanisms of Frailty and Heart Failure with Preserved Ejection Fraction in the Elderly[J].Advances in Cardiovascular Diseases,2022,(9):38.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.010]
[5]赵菲 刘永铭.抗炎类药物对射血分数保留性心力衰竭患者心外膜脂肪组织的影响[J].心血管病学进展,2022,(1):41.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.011]
　ZHAO Fei,LIU Yongming.Effects of Anti-Inflammatory Drugs on Epicardial Adipose Tissue in Patients with Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(9):41.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.011]
[6]张文珺 牛小伟 刘永铭.m6A甲基化在射血分数保留性心力衰竭中的作用的研究进展[J].心血管病学进展,2022,(1):44.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.012]
　ZHANG Wenjun,NIU Xiaowei,LIU Yongming.m6A RNA Methylation in Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(9):44.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.012]
[7]聂琼 吴镜.射血分数保留性心力衰竭：从机制到治疗[J].心血管病学进展,2022,(3):258.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2022.03.0170]
　NIE Qiong,WU Jing.Heart Failure with Preserved Ejection Fraction:from Mechanism to Treatment[J].Advances in Cardiovascular Diseases,2022,(9):258.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2022.03.0170]
[8]卢甜甜 张轶.射血分数保留性心力衰竭左心室心肌力学变化及评估的研究进展[J].心血管病学进展,2022,(4):331.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.011]
　LU Tiantian,ZHANG Yi?/html>.Changes and Evaluation of Left Ventricular Myocardial Mechanical?n Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(9):331.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.011]
[9]时利英 蒋晖.运动训练在射血分数保留性心力衰竭的应用进展[J].心血管病学进展,2022,(4):344.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.014]
　SHI liying,JIANG hui.Exercise-Based Rehabilitation in Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(9):344.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.014]
[10]石玉姣 熊双 刘春秋 杨晨光 董国菊 刘剑刚.射血分数保留性心力衰竭潜在的分子机制及治疗靶点[J].心血管病学进展,2022,(5):423.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.010]
　SHI Yujiao,XIONG Shuang,LIU Chunqiu,et al.Potential Molecular Mechanisms and Therapeutic Target in Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(9):423.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.010]

更新日期/Last Update: 2021-10-21